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Abstract
Lung disease and elevation of blood glucose are associated with increased glucose concentration in the airway surface liquid (ASL). Raised ASL
glucose is associated with increased susceptibility to infection by respiratory pathogens including Staphylococcus aureus and Pseudomonas
aeruginosa. We have previously shown that the anti-diabetes drug, metformin, reduces glucose-induced S. aureus growth across in vitro airway
epithelial cultures. The aim of this study was to investigate whether metformin has the potential to reduce glucose-induced P. aeruginosa infec-
tions across airway epithelial (Calu-3) cultures by limiting glucose permeability. We also explored the effect of P. aeruginosa and metformin on
airway epithelial barrier function by investigating changes in tight junction protein abundance. Apical P. aeruginosa growth increased with baso-
lateral glucose concentration, reduced transepithelial electrical resistance (TEER) and increased paracellular glucose flux. Metformin pre-treat-
ment of the epithelium inhibited the glucose-induced growth of P. aeruginosa, increased TEER and decreased glucose flux. Similar effects on
bacterial growth and TEER were observed with the AMP activated protein kinase agonist, 5-aminoimidazole-4-carboxamide ribonucleotide.
Interestingly, metformin was able to prevent the P. aeruginosa-induced reduction in the abundance of tight junction proteins, claudin-1 and
occludin. Our study highlights the potential of metformin to reduce hyperglycaemia-induced P. aeruginosa growth through airway epithelial
tight junction modulation, and that claudin-1 and occludin could be important targets to regulate glucose permeability across airway epithelia
and supress bacterial growth. Further investigation into the mechanisms regulating metformin and P. aeruginosa action on airway epithelial
tight junctions could yield new therapeutic targets to prevent/suppress hyperglycaemia-induced respiratory infections, avoiding the use of
antibiotics.
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Introduction
The airway epithelium is covered by a thin layer of surface liquid
(ASL), which is vital for maintaining a healthy respiratory tract.
The ASL contains many potential growth substrates for bacterial
growth including glucose. Glucose concentration in human ASL is
normally ~0.4 mM, 12.5 times lower than that of blood [1]. Air-
way surface liquid glucose concentrations are elevated in individu-
als with respiratory disease including acute viral rhinitis [2],
chronic rhinosinitis [3], chronic obstructive pulmonary disease [4]
and cystic fibrosis [1]. Airway surface liquid glucose concentra-
tions are also increased in experimental and diabetic hypergly-
caemia [2, 5] and are further increased in individuals with both
respiratory disease and diabetes mellitus [1, 6]. Such elevations in
ASL glucose are associated with increased susceptibility to
infection, particularly with S. aureus and Pseudomonas aerugi-
nosa [4, 6, 7].
We developed an in vitro model of airway glucose homoeostasis
and showed that ASL glucose concentration is the net effect of the
paracellular diffusion of glucose from the blood/interstitial fluid
across the airway epithelium into ASL and its removal from ASL by
epithelial uptake through facilitative glucose transporters [8–11]. We
showed that paracellular glucose diffusion was increased not only by
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elevating basolateral glucose concentrations (mimicking hypergly-
caemia of blood/interstitial fluid), but also by inflammation. In human
epithelial cell monolayers, we found that application of either apical
pro-inflammatory cytokines [9] or apical bacterial pathogens [12, 13]
increased paracellular glucose flux, increasing glucose concentrations
in ASL. Under pro-inflammatory conditions, airway epithelial glucose
uptake through apical GLUTs is elevated, but this is insufficient to
compensate for the increased paracellular glucose leak and does not
prevent elevation of ASL glucose concentrations [9]. Control of para-
cellular glucose movement thus appears to be the main rate-limiting
step for maintaining low ASL glucose concentrations.
We have previously shown that pre-treatment of airway epithelial
monolayers with the anti-diabetes drug, metformin, attenuated the
effects of S. aureus on paracellular glucose flux and reduced bacterial
growth in ASL by restricting glucose availability [12]. Reducing glu-
cose permeability could therefore be a therapeutic target in the pre-
vention and treatment of respiratory S. aureus infections.
Epithelial barrier dysfunction during bacterial infections is charac-
terized by alterations in tight junction protein abundance. Tight junc-
tions, the most apically located of the intercellular junctional
complexes, regulate the passage of fluid, ions, macromolecules and
inflammatory cells through the paracellular space between epithelial
cells. Tight junctions are formed by three classes of integral membrane
proteins: claudins, occludins and junctional adhesion molecules.
Directly underneath tight junctions, are another specialized cell–cell
contact domain, adherens junctions, which are mainly composed of
cadherin family members. The composition of these protein com-
plexes regulates epithelial permeability to solutes and ions. Factors
that alter the abundance and localization of specific tight junction pro-
teins within this complex could therefore alter glucose permeability.
The aim of this study was to determine whether metformin also
has the potential to reduce glucose-induced P. aeruginosa infections
across airway epithelial cultures by limiting glucose permeability. We
used the adenocarcinoma cell line, Calu-3, derived from human tra-
cheobronchial submucosal glands, which form a heterogeneous pop-
ulation of mucus (mucin-secreting) and serous (fluid-secreting) cell
types [14, 15]. Calu-3 cells secrete a fluid rich in antimicrobial secre-
tions to suppress bacterial growth [16] and form polarized airway
epithelial monolayers with functional tight junctions expressing many
of the integral membrane proteins found in vivo [17, 18]. We explored
the effect of P. aeruginosa and metformin on airway epithelial barrier
function by investigating changes in tight junction protein abundance.
Materials and methods
Airway epithelial cell culture
The human adenocarcinoma-derived cell line, Calu-3 (from ATCC), was
grown in Eagle’s minimal essential medium plus 10% fetal calf serum,
2 mM L-Glutamine, 100 units/ml penicillin, 100 lg/ml streptomycin, and
1% non-essential amino acids (Sigma-Aldrich, Poole, UK) and incubated
in humidified air containing 5% CO2 at 37°C. Calu-3 cells were seeded
onto clear Costar Transwell inserts (0.45-lm pore size) at 250,000 cells/
cm2 to form confluent polarized monolayers, as previously described
[19]. Experiments were carried out 10–14 days post-seeding. Twenty-
four hours before the experiment, monolayers were washed to remove
the mucus layer and placed in Krebs salt solution consisting of 115 mM
NaCl, 5 mM KCl, 25 mM NaHCO3, 1 mM MgCl2, 1 mM CaCl2 and 5 mM
D-glucose (equilibrated with 5% CO2 to pH 7.4) to remove antibiotics and
components of the media that could influence bacterial growth.
Calu-3 monolayers were pre-treated with (or without) metformin
(0.02 or 1 mM) or 5-aminoimidazole-4-carboxamide ribonucleotide
(AICAR; 0.5 mM), added to the basolateral medium 18 hrs prior to api-
cal inoculation with P. aeruginosa. Metformin was applied to the baso-
lateral membrane to mimic the situation in vivo, in which metformin
would reach the airway epithelium via the blood/interstitial fluid. Calu-3
cells and other bronchial cell types express organic cation transporter 3
on the basolateral membrane which is known to facilitate metformin
uptake [20–22].
Using a chopstick style epithelial voltohmmeter (WPI, Hitchin, UK),
Transepithelial electrical resistance (TEER) measurements were made, a
widely accepted quantitative technique to measure the presence of tight
junctions, the major component of epithelial cell barrier integrity in cell
culture models of epithelial monolayers. Transepithelial electrical resis-
tance measurements quantify the transport of ions across the cells with
paracellular ion transport representing the most substantial contribution
to such readings. An intact cellular barrier displays high TEER values.
Loss of barrier integrity leads to decreased TEER values.
Airway epithelia – P. aeruginosa co-culture
A single colony of P. aeruginosa strain PA01 was incubated overnight
at 37°C in RPMI media (Life Technologies, Paisley, UK) and diluted with
glucose-free RPMI to produce a culture of approximately 107 colony
forming units (CFU) per ml. 100 ll of PA01 culture (1 9 106 CFU total)
was applied to the apical surface of Calu-3 monolayers. Co-cultures
were bathed in Krebs salt solution. Normal blood glucose or hypergly-
caemia was modelled by applying basolateral glucose concentrations of
5 and 15 mM respectively. Co-cultures were placed in a CO2 incubator
at 37°C for 7 hrs, after which either cell lysates were collected for Wes-
tern blotting or cells were homogenized and CFU calculated by plating
out serial dilutions. Bacterial growth was external in the ASL, with mini-
mal epithelial invasion observed after 7 hrs.
Paracellular L-glucose flux experiments
Paracellular movement of glucose across Calu-3 monolayers was mea-
sured by analysis of radiolabelled [14C]-L-glucose transepithelial flux.
Experiments were initiated by adding 1 ml of Krebs salt solution con-
taining 1.0 lCi of [14C]-L-glucose plus 10 mM of non-radiolabelled
equivalent glucose to the basolateral side of the transwells and 0.1 ml
of glucose-free Krebs salt solution to the apical side. Apical and basolat-
eral samples were taken after 1 hr and the concentration of radiola-
belled glucose was analysed using a scintillation counter.
Western blotting for tight junction proteins
After cells were co-cultured they were lysed in ERK Phosphorylated buf-
fer containing 20 mM Tris-HCL pH 7.5, 150 mM NaCl, 1 mM
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ethylenediaminetetraacetic acid, 50 mM NaF, 1 mM NaVO4, 1% w/v Tri-
ton-X, 0.5% w/v sodium deoxycholate, 0.1% w/v SDS, 1 lg/ml protease
inhibitor cocktail (P8340; Sigma-Aldrich). Cells were sonicated and cell
debris was removed by centrifugation at 10,000 9 g at 4°C for 10 min.
Total protein concentration was determined by Bradford Assay and
between 30 and 60 lg was electrophoresed on NuPage Novex 10%
Bis-Tris Protein Gels (Invitrogen, Paisley, UK). Protein was then trans-
ferred for 70 min. onto polvinylidene difluoride membranes (Merck Mil-
lipore, Watford, UK). Non-specific reactivity was blocked in Odyssey
Blocking Buffer diluted 1:1 in PBS for 1 hr at room temperature. Blots
were incubated overnight with the following antibodies obtained from
Life Technologies and used at 1:500 dilution; mouse anti-E-Cadherin
(33-4000), rabbit anti-Claudin-1 (51-9000) and rabbit anti-Occludin (H-
279; Santa Cruz Biotechnology, Heidelberg, Germany). The blots were
then washed in Tris-buffered saline/0.2% Tween 20 and incubated with
either Donkey antimouse IgG (926-3221; LI-COR Biosciences, Cam-
bridge, UK) or goat anti-rabbit IgG (LI-COR Biosciences) for 1 hr at
room temperature and kept in the dark. Blots were subsequently probed
with a mouse monoclonal antibody to b-actin. Detection of antigen–anti-
body complexes was assessed using a Licor Odyssey Western blot
imaging system. Integrated density of each fluorescent band was deter-
mined using Image Studio Lite Ver 3.1 (Licor). Results are expressed
as a ratio to b-actin control within the same sample.
Chemicals and reagents
All chemical and reagents were obtained from Sigma-Aldrich unless
otherwise stated.
Statistical analysis
Values are reported as mean  S.E.M. Statistical analysis was per-
formed with ANOVA and post hoc Tukey’s or Student’s t-test. P-values
<0.05 were considered significant.
Results
Metformin- and AMP-activated protein kinase
agonist AICAR restrict glucose-induced
P. aeruginosa growth in airway epithelia-
bacteria co-cultures
Elevating basolateral glucose from 5 to 15 mM in Calu-3 airway
epithelial co-cultures increased apical P. aeruginosa growth by
66  12% (P < 0.01; n = 5; Fig. 1A). Pre-treatment of the epithe-
lium with 1 mM metformin (18 hrs) significantly reduced apical
P. aeruginosa growth in the presence of normoglycemic (5 mM) and
hyperglycaemic (15 mM) basolateral glucose concentrations
(P < 0.05; n = 5). A significant reduction in hyperglycaemic-induced
P. aeruginosa growth was also observed using clinically relevant con-
centrations of metformin (Fig. 1B; 20 lM metformin; usual met-
formin dose is approximately 15–30 mg/kg/day, producing plasma
concentrations  5–20 lM) [23, 24].
It is well documented that metformin activates AMP-activated pro-
tein kinase (AMPK) [25], which is known to play an important role in
tight junction assembly [26]. In addition the AMPK agonist, AICAR
has previously been shown to partially prevent tight junction disas-
sembly (induced by calcium depletion) [27]. We therefore tested the
effect of epithelium pre-treatment with AICAR (0.5 mM, 18 hrs) and
found that this also reduced P. aeruginosa growth by 52  9% under
hyperglycaemic conditions (P < 0.05; n = 6; Fig. 1B).
Metformin attenuates the effects of
P. aeruginosa on Calu-3 TEER and transepithelial
glucose flux
Pre-treatment with 1 mM metformin increased Calu-3 monolayer
TEER from 676  33 to 756  54 O/cm2 (P < 0.05; n = 5;
Fig. 2A). The addition of P. aeruginosa to the apical surface produced
a significant decrease in TEER to 477  21 O/cm2 after 6 hrs of co-
culture (P < 0.01; n = 5; Fig. 2A). Metformin treatment (both 1 mM
and 20 lM) attenuated the fall in TEER produced by apical P. aerugi-
nosa (P < 0.05; n = 5–6), which was prevented by pre-treatment
with the AMPK inhibitor compound C (Fig. 2B). AICAR pre-treatment
also attenuated the P. aeuringosa-induced reduction in Calu-3 TEER
(P < 0.05; n = 6; Fig. 2B).
The decrease in TEER evoked by apical P. aeruginosa induced an
increase in the rate of basolateral-to-apical paracellular glucose flux
by 47.6  5.8% (P < 0.01, n = 4; Fig. 2C), which could be partially
overcome following metformin treatment (P < 0.05; n = 4). Met-
formin had no significant effect on paracellular glucose flux in the
absence of P. aeruginosa (P > 0.05; n = 4; Fig. 2C), despite increas-
ing Calu-3 TEER, consistent with the non-linear relationship between
TEER and paracellular glucose permeability (large changes in TEER
are required at high TEER to induce small changes in paracellular flux;
conversely small changes in TEER at low TEER produce relatively
large changes in paracellular flux) [8].
Metformin increases claudin-1 and occludin
protein abundance to prevent P. aeruginosa-
induced tight junction disruption
We investigated the effects of P. aeruginosa and metformin on the
abundance of tight junction (claudin-1 and occludin) and adherens
junction (E-cadherin) proteins.
Claudin-1 protein abundance was elevated by 16  8% after
18 hrs in the presence of 1 mM metformin (P < 0.05; n = 4;
Fig. 3A). Co-culture with P. aeruginosa produced a small decline in
claudin-1 abundance (P < 0.05; n = 4), although this could be over-
come by metformin pre-treatment (P < 0.01; n = 4).
Metformin pre-treated Calu-3 cells exhibited significantly
increased occludin abundance by 38  9% compared to the
untreated controls (P < 0.01; n = 7; Fig. 3B). Pseudomonas aerugi-
nosa addition resulted in reduced abundance of occludin (65 kD
band), as well as the appearance of occludin cleavage fragments
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consistent with previous studies of P. aeruginosa-induced changes in
airway epithelia tight junctions [28]. Interestingly, the abundance of
the P. aeruginosa-induced occludin cleavage fragments (~45 kD and
~35 kD) was significantly reduced by metformin pre-treatment (by
34  7% and 18  5%, respectively; P < 0.05; n = 4).
E-cadherin abundance was not significantly altered by either met-
formin or P. aeruginosa addition (P > 0.05; n = 3; Fig. 3C).
Discussion
Our study highlights the potential of metformin to reduce hyper-
glycaemia-induced P. aeruginosa growth through modulation of
airway epithelial tight junctions. Metformin pre-treatment of Calu-
3 airway epithelial cells reduced hyperglycaemia-induced apical
P. aeruginosa growth consistent with our previous observations
where metformin decreased hyperglycaemia-induced apical S. au-
reus growth on H441 and primary human bronchial epithelial
cells (HBEC) [12]. A similar attenuation of P. aeruginosa-induced
changes in TEER and restricted bacterial growth were observed
with the AMPK agonist, AICAR and metformin failed to signifi-
cantly alter the bacteria-induced reduction in TEER in the pres-
ence of the AMPK inhibitor, compound C. These data therefore
indicate a potential AMPK-dependence in metformin’s ability to
prevent P. aeruginosa-induced impairment of airway epithelial bar-
rier function.
A B C
Fig. 2Metformin prevents the effect of Pseudomonas aeruginosa infection on transepithelial resistance and paracellular glucose flux across the air-
way epithelium. (A) The effect of metformin pre-treatment (MF; 1 mM, 18 hrs prior to addition of P. aeruginosa) on Calu-3 monolayer transepithelial
electrical resistance (TEER; Ω/cm2), in the presence and absence of P. aeruginosa (7 hr co-culture), under normoglycaemic conditions (5 mM baso-
lateral glucose), n = 5, *P < 0.05, **P < 0.01. (B) The effect of metformin (MF; 20 lM or 1 mM, 18 hr pre-treatment), AICAR (0.5 mM, 18 hr
pre-treatment) and AMPK inhibitor compound C (CC; 80 lM pre-treatment for 1 hr prior to addition of metformin) on Calu-3 monolayer TEER (per-
centage compared with mean TEER in uninfected control Calu-3 cultures) in co-culture with P. aeruginosa (7-hr co-culture), under normoglycaemic
conditions (5 mM basolateral glucose), n = 6, *P < 0.05, **P < 0.01. (C) Paracellular glucose flux across uninfected and P. aeruginosa infected
Calu-3 monolayers, with and without pre-treatment with 1 mM metformin. Paracellular flux measured by adding radiolabelled L-glucose to the baso-
lateral surface and monitoring its appearance at the apical surface, n = 4, *P < 0.05.
A B
Fig. 1Metformin and AMPK agonist AICAR inhibits hyperglycaemia-induced Pseudomonas aeruginosa growth across Calu-3 airway epithelial mono-
layers. (A) Airway epithelia-bacteria co-cultures grown in the presence of 5 or 15 mM basolateral glucose, without (grey bars) or with pre-treatment
with 1 mM metformin (MF; 18 hr pre-treatment; black bars). Bacterial CFU were measured 7 hrs after infection (percentage compared with mean
growth in the presence of 5 mM basolateral glucose control), n = 4, *P < 0.05. (B) Airway epithelia-bacteria co-cultures grown in the presence of
15 mM basolateral glucose, without (grey bars) or with pre-treatment with metformin (MF; 20 lM or 1 mM, 18 hr pre-treatment; black bars) or
AICAR (0.5 mM, 18 hr pre-treatment; hatched bars). Bacterial CFU were measured 7 hrs after infection (percentage compared with mean growth in
the presence of 15 mM basolateral glucose control), n = 6, *P < 0.05, **P < 0.01 compared to 15 mM basolateral glucose control.
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Metformin increased occludin and claudin-1 abundance which
correlated with increased TEER and reduced paracellular glucose flux
across Calu-3 cells. The route by which glucose crosses airway
epithelial tight junctions has not been defined. We have shown that,
although glucose permeability is related to TEER which is a measure-
ment of ionic permeability it is not a direct linear relationship [8].
Moreover, permeability of ions can be restricted by the presence of
specific tight junction proteins which influence charge selectivity of
the tight junction [29]. Thus, the alterations in tight junction composi-
tion that determine glucose permeability as a larger non-ionic solute
are likely to be different to that of ions. Exploring the tight junction
proteins modified by metformin to reduce glucose permeability in the
presence of bacteria may highlight key proteins involved in regulating
paracellular glucose movement.
Pseudomonas aeruginosa addition reduced the abundance of full-
length occludin (~65 kD) and produced occludin-cleavage products
consistent with previous reports [28]. Furthermore, we showed that
this was associated with increased glucose permeability confirming
previous findings that reduced abundance of occludin increased the
permeability of epithelial cells to ethanolamine and mannitol, non-
charged solutes of similar size to glucose [30].
Cleavage of occludin was shown to occur via TLR-2-dependent
activation of calpains in airway epithelial cell monolayers co-cultured
with P. aeruginosa strain PA01 [28]. The abundance of cleaved occlu-
din proteins was significantly reduced by metformin, suggesting that
metformin may inhibit this pathway. Metformin is known to have anti-
inflammatory effects in airway epithelial cells [31] and in a study of
30 diabetic patients, those on metformin therapy exhibited lower
blood TLR-2 expression [32]. Calpains are Ca2+-dependent proteases
that are ubiquitously expressed in cells and tissues. Knockdown of
calpains 1 and 2 reduced cleavage of occludin in epithelial cells [28].
Currently, there is no evidence for any effect of metformin on calpain
activity in airway cells although metformin treatment efficacy in
patients has been linked with polymorphisms in the gene for calpain-
10 [33].
Claudin-1 abundance was also reduced in the presence of
P. aeruginosa, which has similarly been shown to be regulated by
TLR2-dependent signalling pathways in Calu-3 cells [34]. Claudin-1
is expressed ubiquitously in most epithelial tissues of the body
[35], including the airway epithelium and to a lesser extent the
alveolar epithelium [36, 37]. In vitro studies have shown that clau-
din-1 acts predominantly as a barrier-forming tight junction pro-
tein, with overexpression leading to an increase in TEER [38, 39].
Knockout of claudin-1 in mice leads to loss of the tight junctional
barrier to water and macromolecules across the epidermis [40].
Consistent with our findings, downregulation of claudin-1 increased
paracellular permeability to non-charged molecules in airway
epithelial cells [41].
Interestingly, TLR2 agonists were able to modify claudin-1
expression through atypical PKC f [34], which is a known target of
AMPK in alveolar epithelial cells [42]. Given that metformin is an
AMPK agonist, and similar effects on TEER and bacterial growth were
produced by the AMPK agonist AICAR, it is possible that claudin-1
expression is regulated by metformin through AMPK-dependent
phosphorylation of PKC f.
The changes in abundance shown in this study highlight poten-
tial roles for claudin-1 and occludin in the action of metformin to
prevent the P. aeruginosa-induced increase in glucose permeability
and hyperglycaemia-induced growth. Although metformin treatment
is likely to affect other tight junction proteins, both claudin-1 and
occludin could be important targets to reduce glucose permeability
across airway epithelia and supress bacterial growth. Further
A B C
Fig. 3Metformin attenuates Pseudomonas aeruginosa-induced cleavage of epithelial occludin and increases claudin-1 abundance. Calu-3 airway epithe-
lial monolayers with and without 1 mM metformin pre-treatment (18 hrs), were infected with PA01 for 7 hrs, in the presence of 5 mM basolateral glu-
cose. (A) Claudin-1 Western blot band densities normalized against b-actin control and expressed as comparison to untreated Calu-3 control lysates,
n = 4, *P < 0.05, **P < 0.01. (B) Occludin Western blot band (65 kD) densities normalized against b-actin control and expressed as comparison to
untreated Calu-3 control lysates, n = 7, *P < 0.05, **P < 0.01. Arrows indicate ~35 and 45 kD occludin cleavage fragments. (C) E-cadherin Western
blot band densities normalized against b-actin control and expressed as comparison to untreated Calu-3 control lysates, n = 3.
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investigation into the mechanisms regulating metformin and
P. aeruginosa action on airway epithelial tight junctions are now
required. Such studies could yield potential alternatives to antibi-
otics to prevent/suppress hyperglycaemia-induced respiratory infec-
tions.
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